Prior studies have demonstrated a decreased humoral response in solid organ transplant recipients (SOTRs) to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) messenger RNA (mRNA) vaccination (17% antibody response after dose 1 [D1], 54% after dose 2 [D2]) compared with the general population (100%). However, these studies were dominated by kidney transplant recipients and included only a small percentage of liver transplantation (LT) recipients (19.6%).^(1-4) Because LT recipients often receive milder induction and maintenance immunosuppression, they may have a more robust humoral response. To investigate this, we studied SARS-CoV-2 antibody development in a cohort of LT recipients who completed a 2-dose mRNA vaccine series of either mRNA-1273 (Moderna, Cambridge, MA) or BNT162b2 (Pfizer-BioNTech, New York, NY).

先前的研究表明，实体器官移植受者 (SOTR) 对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 信使 RNA (mRNA) 疫苗接种的体液反应降低（第 1 剂 [D1] 后抗体反应为 17%，与一般人群 (100%) 相比，剂量 2 [D2]) 后为 54%。然而，这些研究以肾移植受者为主，仅包括一小部分肝移植 (LT) 受者 (19.6%)。^{( 1-4 )}由于 LT 接受者通常接受较温和的诱导和维持免疫抑制，因此他们可能有更强烈的体液反应。为了研究这一点，我们研究了一组 LT 接受者的 SARS-CoV-2 抗体发展，这些接受者完成了 mRNA-1273（Moderna，Cambridge，MA）或 BNT162b2（Pfizer-BioNTech，New York，纽约）。